2007 Presentations

UBC scientists participate in scientific and clinical meetings around the world. To learn more about a presentation, please contact the UBC scientist directly or call 301-654-9729.

  • The Gerontological Society of America’s 60th Annual Scientific Meeting

    Nov 16 - Nov 20 2007
    San Francisco, CA, USA
    www.agingconference.com/

    Presented as part of the symposium: "Ethics of Dementia Screening"
    Whether and Where to Screen for Dementia
    Frank L¹, Khachaturian Z², Borson S³, Boustani M4, Dash P5, Ashford W    6
    ¹United BioSource Corporation,     Bethesda, MD, USA
    ²Alzheimer's Association's Ronald & Nancy Reagan Research Institute, Potomac, MD, USA
    ³Memory Disorders Clinic and the ADRC Satellite University of Washington, St. Louis, MO, USA
    4Indianapolis Discovery Network for Dementia Scientist, Regenstrief Institute, Inc. Center Scientist, Indiana University Center for Aging Research, Indianapolis, IN, USA
    5Department of Neurology, Johns Hopkins, Baltimore, MD, USA
    6Stanford/VA Aging Clinical Research Center, Palo Alto, CA, USA

    Presented as part of the symposium: "Research Directions to Support Global Dementia Screening"
    Capturing Comprehensive Outcomes through Study Design
    Ashford W¹, Mendiondo M², Shankle W³, Frank L4, Khachaturian Z    5
    ¹Stanford/VA Aging Clinical Research Center,     Palo Alto, CA, USA
    ²University of Kentucky, Lexington, KY, USA
    ³University of California, Irvine, CA, USA
    4United BioSource Corporation, Bethesda, MD, USA
    5Alzheimer's Association's Ronald & Nancy Reagan Research Institute, Potomac, MD, USA

  • CHI: Drug Safety Strategies: Best Practices to Mitigate Risks throughout the Product's Life Cycle

    Nov 13 - Nov 14 2007
    Philadelphia, PA, USA
    www.healthtech.com

    Panel Discussion: "Costs and Opportunities of Phase IV Risk Management Programs"
    Gerald A. Faich, MD, Senior Vice President, Epidemiology & Risk Management, United BioSource Corporation, Blue Bell, PA, USA

    Leveraging Drug Registry Tools to Assess Safety and Performance
    Annette Stemhagen, DrPH FISPE, Vice President, Epidemiology & Risk Management, United BioSource Corporation, Blue Bell, PA, USA

  • American Academy of Pediatrics’ (AAP) 2007 National Conference & Exhibition

    Oct 27 - Oct 30 2007
    San Francisco, CA, USA
    www.aap.org

    Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab Among Preterm Infants After Valuing a Reduction in Persistent Wheezing
    Polak MJ¹, Cragin LS², Groothuis JR³ , McLaurin KK³, Sorensen SV², Mahadevia PJ³ 
    ¹Department of Pediatrics, West Virginia University School of Medicine, Morgantown, WV, USA
    ²United BioSource Corporation, Center for Health Economics, Epidemiology & Science Policy, Bethesda, MD, USA
    ³MedImmune, Inc., Health Outcomes and Pharmacoeconomics, Gaithersburg, MD, USA

  • 15th UEGW 2007 (United European Gastroenterology Week)

    Oct 27 - Oct 31 2007
    Paris, France
    www.uegw.org/

    Poster Presentation
    Reduction in Health Resource Utilization with Cyclooxygenase-2 Inhibitor Parecoxib Compared to Opioids after Noncardiac Surgery in the UK
    Remak E¹, Muszbek N¹, Manson S¹, G. Zlateva², C. Chen²
    ¹United BioSource Corporation,     London, UK
    ²Pfizer Inc, New York, NY, US

  • ISPOR 10th Annual European Congress

    Oct 20 - Oct 23 2007
    Dublin, Ireland
    www.ispor.org/Events/Index.aspx?eventId=21

    Short Courses

    Saturday, Oct 20, 2007

    Discrete Event Simulation for Economic Analyses
    Faculty:     J. Jaime Caro MDCM, FCRPC, FACP, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal PQ and Scientific Director, Caro Research Institute, Concord, MA, USA; Jörgen Möller MSc Mech Eng, Simulation Specialist, Caro Research Institute, Concord, MA, USA
    Course Description:     This course will provide a basic understanding of the key concepts of discrete event simulation. The focus will be on the use of these simulation models to address pharmacoeconomic (and device-related) problems. The course will be structured around practical exercises. Topics to be covered are: Why DES? Dynamic simulation as a tool; Components of a DES; How do you build a model? Modeling of processes and resource use; Modeling of variables and decisions. If time permits, simple animation will be demonstrated. We will use ARENA to build simple models. Instructors will distribute training versions of Arena. This course is designed for those with some experience with modeling. 

    Instrument Development & Evaluation for Patient-Reported Outcomes Assessment
    Faculty:     Andrew Lloyd M. Phil, Research Scientist and Deputy Director, United BioSource Health Care Analytics Group – Europe, London, UK;     Patricia van Hanswijck de Jonge PhD, MSc; Senior Research Associate, Health Care Analytics Group, United BioSource Corporation, London, UK
    Course Description: Patient-Reported Outcomes (PRO) instrument development and evaluation includes psychometric analyses including the use of factor analysis and other techniques. This course will cover the recent draft guidance from the FDA as well as existing guidance from the EMEA regarding instrument development.     This course is designed for those with some experience with using PRO instruments.

    Workshop Presentations

    Sunday, Oct 21, 3007- Workshops Session I:

    Risk Factors That Change Over Time: How to Estimate Their Impact on the Occurrence of Health Outcomes
    Ishak I, PhD, Director, Biostatistics, Caro Research Institute, Montreal, QC, Canada; Huybrechts KF, MS, Senior Researcher, Caro Research Institute, Concord, MA, USA; Caro JJ, MDCM, FRCPC, FAC, President & Scientific Director, Caro Research Institute, Concord, MA, USA.

    Podium Presentations

    Monday, Oct 22, 2007- Podium Session II: Surgery

    Cost-Effectiveness of Cyclooxygensae-2 Inhibitor Parecoxib Compared to Opioids After Noncardiac Surgery in the UK
    Remák E¹, Muszbek², Manson SC², Zlateva G4, Chen C4; ¹United Biosource Corporation, Budapest, Hungary; ²UnitedBiosource Corporation, London, UK, ³Pfizer Inc, New York, NY, USA

    Micro-Costing of Surgical Procedures Related to Intracerebral Haemorrhage in a UK Health Care Setting
    Manson SC¹, De Cock E², Jenkins AJ³, Twena N4; ¹United BioSource Corporation, London, UK; ²United BioSource Corporation, Barcelona, Spain; ³Newcastle General Hospital, Newcastle upon Tyne, UK; 4Novo Nordisk Ltd, Crawley, West Sussex, UK

    Monday, Oct 22, 2007- Podium Session IV: Economics of Neurological Disease

    Modeling Treating Multiple Sclerosis with Disease Modifying Drugs Using Discrete Event Simulation
    Guo S¹, Copur D¹, Ward A¹, Bennett R², Al-Sabbah A², Meletiche DM², Caro JJ¹; ¹Caro Research Institute, Concord, MA, USA; ²EMD Serono, Inc., Rockland, MA, USA

    Poster Presentations

    Session I: Sunday, Oct 21, 2007

    Switching from Branded to Generic Risperidone in Patients with Schizophrenia: An Estimation of Potential Economic Consequences in the Netherlands
    Van Nooten F¹, Rijnders C², Brown R³, Van Agthoven M4; ¹United BioSource Corporation, Brussels, Flanders, Belgium; ²Institute for Mental Health Care Midden Brabant, Tilburg, Noord-Brabant, The Netherlands; ³United BioSource Corporation, London, London, UK;  4Janssen-Cilag BV, Tilburg, The Netherlands

    Time Spent on Anaemia Management with Erythropoietin Stimulating Agents (ESA) in Haemodialysis Centres: A Cross-Countries Perspective
    De Cock E¹, Van Nooten F², Sapède C³, Dale P4, Petrillo J5, Werner M6; ¹United BioSource Corporation, Barcelona, Spain; ²United BioSource Corporation, Brussels, Belgium; ³F. Hoffmann-La Roche Ltd, Basel, Switzerland; 4United Biosource, London, England, UK; 5United BioSource Corporation, Bethesda, MD, USA; 6United BioSource Corporation, Seattle, WA, USA

    Selection of Utility Instruments for Asthma and Chronic Obstructive Pulmonary Disease (COPD)
    Lloyd A, Meguro M; United BioSource Corporation,     London, UK

    Cost-Effectiveness of Duloxetine vs. Venlafaxine XR and SSRIS in Patients with Major Depressive Disorder in Primary and Secondary Care in Spain
    De Cock E¹, Benedict A², Le TK³, Sacristán del Castillo JA4, Dilla T5; ¹United BioSource Corporation, Barcelona, Spain; ²United BioSource Corporation, Budapest, Hungary; ³Eli Lilly and Company, Indianapolis, IN, USA; 4Lilly S.A, Madrid, Spain; 5Eli Lilly Spain, Alcobendas, Spain

    Simulation of Long-Term Costs of Complications in Type II Diabetes in the United States
    Ward A, Kongnakorn T, Moller J, O'Brien JA, Caro JJ; Caro Research Institute, Concord, MA, USA

    Potential Drug-Drug Interactions with Risperidone and the Risk of Discontinuation: A retrospective Analysis of Patients in Quebec, Canada
    Ishak KJ¹, Glass JR², Tan Y¹, Luong D², Caro JJ³; ¹Caro Research Institute, Montreal, QC, Canada; ²Janssen-Ortho Inc, Toronto, ON, Canada; ³Caro Research Institute, Concord, MA, USA

    Session II: Monday, Oct 22, 2007

    Sunitinib vs. Interferon-Aplha (IFN-Α) In First-Line Metastatic Renal Cell Carinoma (MRCC): An Economic Evaluation
    Remák E¹, Brown R², Negrier S³, Motzer RJ4, Kim ST5, Charbonneau C6; ¹United Biosource Corporation, Budapest, Hungary; ²United BioSource Corporation, London, London, UK; ³Centre Leron Berard, Lyon, France; 4Memorial Sloan Kettering Cancer Center, New York, NY, USA; 5Pfizer Inc, San Diego, CA, USA; 6Pfizer Inc, New York, NY, USA

    Cost-Effectiveness of Sunitinib as Second Line Treatment in Patients with Metastatic Renal Cancer in Belgium
    Van Nooten F¹, Dewilde S¹, Van Belle S², Marbaix S³; ¹United BioSource Corporation, Brussels, Belgium; ²University Hospital Ghent, Gent, Belgium; ³Pfizer, Brussels, Belgium

    Cost-Utility Analysis of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Hungary
    Muszbek N¹, Odhiambo R²; ¹UnitedBiosource Corporation, London, UK;  ²sanofi-aventis Zrt, Budapest, Hungary

    Cost-Effectiveness Analyses of Rufinamide vs. Topiramate and Lamotrigine as Adjunctive Therapies in the Treatment of Lennox-Gastaut Syndrome (LSG) in the UK
    Benedict Á¹, Dale PL², MacLaine G³, Verdian L³; ¹United BioSource Corporation, Budapest, Hungary; ²United BioSource Corporation, London, UK; ³Eisai Europe Limited, Hatfield, Herthfordshire, UK

    UK     Cost-Effectiveness Analyses of Docetaxel Versus Generic Paclitaxel Once Weekly and Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Breast Cancer (MBC) Progessed After Anthracycline Chemotherapy
    Benedict Á¹, Cameron D², Corson H³, Jones S4; ¹United BioSource Corporation, Budapest, Hungary; ²University of Leeds, Leeds, UK; ³sanofi-aventis, Bagneux, France; 4US Oncology Research, Houston, TX, USA

    Modeling the Clinical and Economic Consequences of Treating Relapsing Form of Multiple Sclerosis with Subcutaneous Versus Intramuscular Interferon-Beta-1A
    Guo S¹, Copur D¹, Ward A¹, O'Brien JA¹, Ishak KJ², Bennett R³, Al-Sabbah A³, Meletiche DM³, Caro JJ¹; ¹Caro Research Institute, Concord, MA, USA; ²Caro Research Institute, Montreal, QC, Canada; ³EMD Serono, Inc, Rockland, MA, USA

    Session III: Tuesday, Oct 23, 2007

    Hospital Costs for Treatment of Acute Heart Failure: Economic Analysis of the REVIVE II Study
    De Lissovoy G¹, Fraeman K¹, Mullahy J², Durtschi A³, Sterz R4, Salon J5; ¹United BioSource Corporation, Bethesda, MD, USA; ²University of Wisconsin, Madison, WI, USA; ³Abbott Laboratories, Powell, OH, USA; 4Abbott GmbH & Co. KG, Ludwigshafen, Germany; 5Abbott Laboratories, Columbus, OH, USA

    Resource Use and Treatment Costs for Acute Decompensated Heart Failure: Economic Analysis of the SURVIVE Trial
    De Lissovoy G¹, Fraeman K¹, Sterz R², Salon J³; ¹United BioSource Corporation, Bethesda, MD, USA; ²Abbott GmbH & Co. KG, Ludwigshafen, Germany; ³Abbott Laboratories, Columbus, OH, USA

    Eliciting Utility Scores for Health States Associated with Severe Chronic Pain
    Lloyd A¹, Meguro M¹, Dewilde S², MacLaine G³, Verdian L³; ¹United BioSource Corporation, London, UK; ²United BioSource Corporation, Brussels, Belgium; ³Eisai Europe Limited, Hatfield, Herthfordshire, UK

    Major Bleed Resource Use and Costs for Patients Hospitalized with Acute Coronary Syndrome in France, Italy and Spain
    Brown R¹, Parnaby A², Guijarro P³, Nachit-Ouinekh F², Bamfi F4; ¹United BioSource Corporation, London, UK; ²GlaxoSmithKline, Paris, France; ³GlaxoSmithKline, Madrid, Spain; 4GlaxoSmithKline Spa, Verona, Veneto, Italy

    Costs of Major Bleeds in Acute Coronary Syndrome Patients
    Brown R¹, Ferrari E², Drogoul L², Nachit-Ouinekh F³, De Cock E4; ¹United BioSource Corporation, London, London, UK, ²Hopital Pasteur, Nice, France; ³GlaxoSmithKline, Paris, France; 4United BioSource Corporation, Barcelona, Spain

    Cost-Effectiveness of Linezolid vs. Vancomycin in Nosocomial Pneumonia Due to Suspected Methicillin-Resistant Staphylococcus Aureus in France
    De Cock E¹, Timsit JF², Carlet J³, Leroy O4, Wolff M5, Levrat F6; ¹United BioSource Corporation, Barcelona, Spain; ²Hôpital Albert Michallon, Grenoble, France; ³Groupe Hospitalier Paris Saint Joseph, Paris, France; 4Hôpital Guy Chatiliez, Tourcoing, France; 5Hôpital Bichat Claude Bernard, Paris, France; 6Pfizer, Paris, France

    Cost-Effectiveness of  Linezolid vs. Vancomycin in Complicated Skin and Soft-Tissue Infection Due to Suspected Methicillin-Resistant  Staphylococcus Aureus in France
    De Cock E¹, Besnier JM², Dupon M³, Guéry B4, Levrat F5; ¹United BioSource Corporation, Barcelona, Spain; ²CHRU Bretonneau, Bretonneau, France; ³Hôpital Pellegrin, Bordeaux, France; 4Hôpital Calmette, CHRU Lille, Lille, France; 5Pfizer, Paris, France

    Retrospective Study of Complications and Resource Use in Endovascular Management of AAA
    Muszbek N¹, Van Sambeek MR², Soong CV³, Thompson MM4, Gavriel S¹, Hutton J5, Brasseur P6; ¹United BioSource Corporation, London, UK; ²Erasmus University Medical Center, Rotterdam, The Netherlands; ³Belfast City Hospital, Belfast, UK; 4St. George’s Hospital NHS Trust, London, UK; 5University of York, York, UK; 6Medtronic International SA, Tolochenaz, Switzerland

    Adult Asthma: A Cohort Analysis of Use and Cost of Hospital and Emergency Department Care by Location of Residence Over Twelve Months
    O'Brien JA, Duran PA, Caro JJ; Caro Research Institute,     Concord, MA, USA

    Probabilistic Sensitivity Analysis in Health Economic Modeling Studies: A Quality Assessment
    Getsios D¹, Ishak KJ², Finnegan S³, Caro JJ³; ¹Caro Research Institute, Halifax, NS, Canada; ²Caro Research Institute, Montreal, QC, Canada; ³Caro Research Institute, Concord, MA, USA

    Reducing Global Cardiometabolic Risk in Overweight or Obese Individuals with Dyslipidemia: Projected Benefits of Rimonabant in A Real World Population

    Getsios D¹, McEwan P³, Danel A4, Moller J², Ishak KJ5, Caro JJ²; ¹Caro Research Institute, Halifax, NS, Canada; ²Caro Research Institute, Concord, MA, USA; ³Cardiff Research Consortium, Cardiff, UK; 4Sanofi-Aventis, Paris, France; 5Caro Research Institute, Montreal, QC, Canada

    Simple Sensitivity Analysis to Assess the Impact of Rounding on Blood Pressure Measurements on Estimates of Control Rates
    Ishak KJ¹, Payne K¹, Caro JJ², Khan ZM³, Daley WM³, Califf R4; ¹Caro Research Institute, Montreal, QC, Canada; ²Caro Research Institute, Concord, MA, USA; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 4Duke Clinical Research Institute, Durham, NC, USA

    Economic Training Advantages of Online Discrete Event Simulation
    Hunting B¹,     Moller J²; ¹United BioSource Corp., Montreal, Quebec, Canada; ²United BioSource Corp., Väggarp, Eslöv, Sweden

  • ECNP 20th Annual Congress

    Oct 13 - Oct 17 2007
    Vienna, Austria
    www.ecnp.eu
    Poster Presentations
    Effect of Comorbidites and Adverse Events on Clinical Global Impressions Ratings
    Busner J¹, Targum SD², Miller DS³
    ¹United BioSource Corporation, and Clinical Associate Professor of Psychiatry Penn State College of Medicine, Wayne, U.S.A..
    ²United BioSource Corporation, and Massachusetts General Hospital, Boston, USA
    ³United BioSource Corporation, Training and Education Group, Wayne, PA, USA

    Determination of Hamilton Anxiety Rating Scale Severity Gradation in Generalized Anxiety Disorder
    ¹United BioSource Corporation s.r.o., Prague, Czech Republic
    ²United BioSource Corporation, Wayne, PA, USA

  • 14th Annual Conference of ISOQOL: Health Related QOL Research: From Measurement to Understanding (ISOQOL 2007)

    Oct 10 - Oct 13 2007
    Toronto, Ontario, Canada
    www.isoqol.org
    Symposium
    (Revicki DA- A discussant of symposium)

    New Perspectives on How Preference-Based Indexes (EQ-5D, HUI2, HUI3, QWB-SA, and SF-6D) Scale Summary Health-Related Quality-of-Life
    Fryback DG¹, Kim JS², Palta M³,     Revicki DA4
    ¹ Population Health Sciences, University of Wisconsin, Madison, WI, USA
    ² Educational Psychology, University of Wisconsin, Madison, WI, USA
    ³Population Health Sciences, University of Wisconsin, Madison, WI, USA
    4Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA

    Workshop Presentations

    Advanced Psychometric Methods, Part 1: Use Of Exploratory and Confirmatory Factor Analyses in Pro Instrument Development and Evaluation
    Dennis Revicki, PhD, Don Stull, PhD; Center for Health Outcomes Research, United BioSource Corporation

    Advanced Psychometric Methods, Part 2: Executing and Interpreting Exploratory and Confirmatory Factor Analyses in Pro Instrument Development and Evaluation
    Don Stull, PhD, Margaret Vernon, PhD; Center for Health Outcomes Research, United BioSource Corporation

    Capturing Patient-Reported Outcomes Electronically: From e-PRO Design to Implementation
    Nancy Kline Leidy, PhD¹, Kellee Howard, MSc¹, Meghan Werner, MPP¹,     Jennifer Petrillo, BS¹, Jacqueline Thong²; ¹Center for Health Outcomes Research, United BioSource Corp.; ²CRF, Inc.

    Poster Presentations

    Psychometric Characteristics of the Daily Sleep Interference Scale Among Diabetic Peripheral Neuropathy and Postherpetic Neuralgia Patients
    Vernon MK¹, Brandenburg NA², Alvir JMJ², Revicki DA¹
    ¹United BioSource Corporation, Bethesda, MD, USA
    ²Pfizer, Inc., New York, NY, USA

    Content Validity and Usability of the Treatment Outcome Score and Mean Complex Severity Score: New Electronic PROs to Assess Symptom Severity and Improvement in Hereditary Angioedema
    Vernon MK¹, Rentz A¹,White M², Schmalbach T³
    ¹United BioSource Corporation, Bethesda, MD, USA
    ²Institute for Asthma & Allergy, Wheaton, MD, USA
    ³Dyax, Corp., Cambridge, MA, USA

    Estimating Utility Values for Symptom Control in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Doyle S¹ , Lloyd A², Gavriel S¹, Lewis G³
    ¹United BioSource Corporation, London, UK
    ²Formerly of United BioSource Corporation
    ³Roche Products Ltd., UK

    COPD and Asthma Fatigue Scale (CAFS): Development and Psychometric Properties
    Flood R ¹, Revicki DA¹, Meads DM², Glendenning GA³, Gale R³, McKenna SP²
    ¹CHOR, United BioSource, Bethesda, MD, USA
    ²Health Outcomes Research, Galen Research, Manchester, UK
    ³Health Economics & Outcomes Research, Novartis Research Center, Horsham, UK

    COPD and Asthma Sleep Impact Scale (CASIS): Development and Psychometric Properties
    Revicki DA¹, Flood R ¹, Meads DM², Glendenning GA³, Gale R³, McKenna SP²
    ¹CHOR, United BioSource, Bethesda, MD, USA
    ²Health Outcomes Research, Galen Research, Manchester, UK
    ³Health Economics & Outcomes Research, Novartis Research Center, Horsham, UK

    Development and Validation of the Asthma Life Impact Scale (ALIS)
    Meads DM², McKenna S¹,     Revicki D², Flood R², Glendenning GA³, Hunter C4
    ¹Health Outcomes Research, Galen Research, Manchester, UK
    ²CHOR, United BioSource, Bethesda, MD, USA
    ³Health Economics & Outcomes Research, Novartis Research Center, Horsham, UK
    4Peterborough District Hospital NHS Trust, Peterborough, UK

    Development and Validation of the Living with COPD (LCOPD) Quality of life (QoL) Measure
    McKenna S¹, Meads DM²,     Revicki D², Flood R², Glendenning GA³, Hunter C4
    ¹Health Outcomes Research, Galen Research, Manchester, UK
    ²CHOR, United BioSource, Bethesda, MD, USA
    ³Health Economics & Outcomes Research, Novartis Research Center, Horsham, UK
    4Peterborough District Hospital NHS Trust, Peterborough, UK

    Preliminary Psychometric Analysis of the PROMIS Pain Behavior Item Bank
    Chen WH¹, Cook KF², Amtmann D³, Revicki DA¹
    ¹Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
    ²Rehabilitation Medicine, University of Washington, Seattle, Houston, TX, USA
    ³Rehabilitation Medicine, University of Washington, Seattle, WA, USA
    Psychometric Analysis of a PROMIS Item Bank for Measuring Pain Interference
    Cook K¹, Chen WH², Revicki DA², Amtmann D³
    ¹Department of Rehabilitation Medicine, University of Washington, Seattle, Houston, TX, USA
    ²Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
    ³Rehabilitation Medicine, University of Washington, Seattle, Seattle, WA, USA
     
    Exploratory Factor Analysis of the PROMIS Pain Quality Item Bank
    Revicki DA¹, Cook K², Amtmann D³, Chen WH¹
    ¹Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
    ²Department of Rehabilitation Medicine, University of Washington, Seattle, Houston, TX, USA
    ³Rehabilitation Medicine, University of Washington, Seattle, Seattle, WA, USA

    Factor Structure of the QOL-AD
    Frank LB¹, Kleinman L², Zhao Y³
    ¹CHOR, United BioSource Corporation, Bethesda, MD, USA
    ²CHOR, United BioSource Corporation, Seattle, WA, USA
    ³Outcomes Research, USMD, Eli Lilly and Company, Indianapolis, IN, USA

    Developing a Tool to Assess Depression and Remission: Focus Group Results
    Frank LB¹, Morlock R², Mannix S¹, Feltner D³, Matza L¹, Werner M4, Hanlon J5, Revicki DA¹
    ¹CHOR, United BioSource Corporation, Bethesda, MD, USA
    ²Outcomes Research, Pfizer, Inc., Ann Arbor, MI, USA
    ³Research, Pfizer, Inc., Ann Arbor, MI, USA
    4CHOR, United BioSource Corporation, Seattle, WA, USA
    5QualityMetric, Lincoln, RI, USA

    Development of a Nocturnal Gastroesphageal Reflux Disease (GERD) Symptom Severity and Impact Instrument
    Roberts L¹, Spiegel BM², Kothari-Talwar S³, Reema Mody³, Revicki DA¹, Kahrilas PJ4, Camilleri ML5, Walter K¹
    ¹BioSource Corporation, Bethesda, MD, USA
    ²Internal Medicine and Digestive Diseases, VA Greater Los Angeles Healthcare System David Geffen School of Medicine, Los Angeles, CA, USA
    ³Health Economics & Outcomes Research, TAP Pharmaceutical Products, Inc., Lake Forest, IL, USA
    4Gastroenterology, Northwestern University, Chicago, IL, USA
    5Medicine, Mayo Clinic, Rochester, MN, USA

    Assessing Symptoms and Health-Related Quality of Life (HRQL) in Pediatric Gastroesophegeal Reflux Disease (GERD)
    Kleinman L¹, Kothari-Talwar S², Roberts L³
    ¹CHOR, United BioSource Corporation, Seattle, WA, USA
    ² Health Economics & Outcomes Research, TAP Pharmaceutical Products, Inc., Lake Forest, IL, USA
    ³ CHOR, United BioSource Corporation, Bethesda, MD, USA
     
    Exploring the Relationship Between HRQL and Visual Acuity Loss in People with Diabetic Retinopathy
    Lloyd A¹, Nafees B¹, Gavriel S¹, Boye KS², Ahmad A³, Rousculp M4,
    ¹United BioSource Corporation, London, UK
    ²Global Health Outcomes, Eli Lilly, Indianapolis, IN, USA
    ³Royal Liverpool University Hospital, Liverpool, UK
    4 Formerly of Eli Lilly, Indianapolis, IN
     
    Meaningful Comparisons Between Ratings of Adolescent’s QOL by Parent and Adolescent
    Huang I-C¹, Shenkman EA¹, Knapp CA¹, Leite W², Revicki D³
    ¹Epidemiology and Health Policy Research, University of Florida, Gainesville, FL, USA
    ²Educational Psychology, University of Florida, Gainesville, FL, USA
    ³Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
     
    The Use of Multidimensional Item Response Theory to Shorten a Diabetes QOL Instrument
    Leite W¹, Huang I-C², Shenkman EA², Wu AW³,     Revicki D4
    ¹Educational Psychology, University of Florida, Gainesville, FL, University of Florida, I-Chan
    ²Epidemiology and Health Policy Research, University of Florida, Gainesville, FL, USA
    ³Health Policy and Management, Johns Hopkins University, Baltimore, MD
    4Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
     
    Validity and Responsiveness of the National Eye Institute Visual Function Questionnaire-25 in Patients withAge-Related Macular Degeneration: Secondary Analysis of Two Clinical Trials
    ¹The Center for Health Outcomes Research, United Biosource Corporation, Bethesda, MD
    ²Health Economics & Outcomes Research, Novartis Pharma AG, CH-4052, Basel, Switzerland

  • 4th World Congress World Institute of Pain

    Sep 25 - Sep 29 2007
    Budapest, Hungary
    www.kenes.com/wip/registration.asp

    Poster Presentation
    Eliciting Utility Scores for Health States Associated with Therapies for Severe Chronic Pain
    A. Lloyd¹, L. Verdian², G. MacLaine²,     M. Meguro¹
    ¹United BioSource Corporation, London, UK
    ² Eisai, Europe

  • The European Cancer Conference 14 (ECCO 14)

    Sep 23 - Sep 27 2007
    Barcelona, Spain
    www.fecs.be/emc.asp

    Poster Presentation
    Economic Evaluation of Sunitinib vs. Interferon-alfa (IFN-a) in First-Line Metastatic Renal Cell Carcinoma (mRCC)
    S Negrier¹, Remák E², Brown R², Kim ST³, Charbonneau C4, Motzer RJ    5
    ¹Centre Léon Bérard, Lyon, France
    ²United BioSource Corporation,     London, UK
    ³Pfizer Global Research and Development, La Jolla, CA, USA
    4Pfizer Inc., New York, NY, USA
    5Memorial Sloan-Kettering Cancer Center, New York, NY, USA

  • European Respiratory Society (ERS) Stockholm 2007 Congress

    Sep 15 - Sep 19 2007
    Stockholm, Sweden
    www.ersnet.org/stockholm-programme

    Thematic Poster Session
    Cost-effectiveness of Omalizumab in Patients with Severe Persistent Allergic (Igemediated) Asthma: Adaptation of Innovate and Etopa Data to the Netherlands
    Brown R, Senior Scientist & Director, United BioSource Corporation, London, UK

  • iHEA - 6th World Congress: Explorations in Health

    Jul 8 - Jul 11 2007
    Copenhagen, Denmark
    www.healtheconomics.org/congress/2007/

    Abstract Presentation
    The Effect Of Different Types Of Survival Curves To Extrapolate Observed Events From A 1-Year Rct To Lifetime - The Case Of Eptifibatide Use In Coronary Stenting
    Dewilde S, United BioSource Corporation, Brussels, Belgium

    Poster Presentation
    Estimating Cost of Hospital Treatment for Patients in a Randomized Clinical Trial
    de Lissovoy G¹, Fraeman K¹, Sterz R², Durtschi A², Mullahy J³
    ¹Center for Health Economics and Policy, United Biosource Corp.,     Bethesda, MD, USA
    ²Abbott Laboratories, Abbott Park, IL, USA
    ³Department of Economics, University of Wisconsin, Madison, WI, USA

  • ISOQOL Conference on Patient Reported Outcomes in Clinical Practice

    Jun 24 - Jun 26 2007
    Budapest, Hungary
    www.isoqol.org

    Poster Presentations
    Tuesday, June 26, 2007 9:30AM-10:15AM
    Monitoring Nasal Congestion: Using the Congestion Quantifier 7-Item (CQ7) to assess change in Patient Symptoms and Their Impact
    Stull D1
    1United BioSource Corporation, Bethesda, MD USA

  • American Diabetes Association (ADA) 2007

    Jun 22 - Jun 26 2007
    Chicago, IL, USA
    www.diabetes.org

    The Link between Visual Acuity and Health-Related Quality of Life among Patients with Diabetic Retinopathy
    Rousculp MD¹, Boye KS¹ ,     Matza LS² , Malley K³ , Olgesby A¹
    ¹Health Outcomes Research, Eli Lilly & Co., ²United BioSource Corp.; ³Malley Research Programming

    Economic analysis of add-on therapy with thiazolidinedione (TZD) versus insulin (INS) to metformin (MET) monotherapy.
    Balu S, Lee WC, Arondekar B, Horblyuk R, Pashos CL

    Budgetary impact of thiazolidinedione (TZD) add-on therapy relative to insulin (INS) add-on therapy in indivduals treated with sulfonylureas (SA): A third party payer's perspective.
    Balu S, Arondekar B, Lee WC, Horblyuk R, Pashos CL.

  • HTAi Conference

    Jun 18 - Jun 20 2007
    Barcelona, Spain

    Poster Presentation
    The Cost-Effectiveness of Pharmacological Treatments for Preventing Relapse in Patients with Bipolar I Disorder
    Y. Bravo Vergel¹, S. Palmer¹, G. Dunn¹ , M. Barbieri¹, S. Beynon², N. Woolacott², K. Soares-Weiser², J. Geddes³, S. Gilbody4
    ¹Centre for Health Economics, University of York, York, U.K.
    ²Centre for Reviews and Dissemination, University of York, York, U.K
    ³Department of Psychiatry, University of Oxford, Oxford, U.K.
    4Department of Health Sciences, University of York, York, U.K.

  • 43rd DIA Annual Meeting

    Jun 17 - Jun 21 2007
    Atlanta, GA, USA
    www.diahome.org
    Sessions
    Using Electronic Medical Records for Clinical Research
    Susan D. Ross, MD, FRCPC, Vice President, Medical Affairs, United BioSource Corporation, Medford, MA, USA
    The Use of Patient & Disease Registries for Product Lifecycle Management
    Co-Chair: Annette Stemhagen, DrPH FISPE, Vice President, Epidemiology & Risk Management, United BioSource Corporation, Blue Bell, PA, USA
    Avoiding Pitfalls in the Conduct of Postmarketing Trials for Safety
    Chair: Gerald A. Faich, MD, Senior Vice President, Epidemiology & Risk Management, United BioSource Corporation, Blue Bell, PA, USA

  • Hematology Oncology Pharmacy Association (HOPA)

    Jun 14 - Jun 16 2007
    Denver, CO

    Presentation

    Drug cost considerations for erythroprietic stimulating therapies (ESTs) agents in patients initiated at FDA-approved dosing: Results from practice patterns in a prospective observational study.
    Pashos CL, Wang Q, Larholt K, Bookhart B, McKenzie RS, Piech CT.

  • European League Against Rheumatism (EULAR) Congress 2007

    Jun 13 - Jun 16 2007
    Barcelona, Spain
    www.eular.org/

    Norm-Based Interpretation of SF-36 Improvements for Adalimumab plus Methotrexate (MTX) Combination Therapy Versus MTX Alone In Early Rheumatoid Arthritis 
    Kimel M², Cifaldi M¹, Chmiel J¹, Chen N¹, and Revicki D²
    ¹Abbott Laboratories, Abbott Park, USA
    ²United BioSource Corporation, MD, USA

  • NCDEU Annual Meeting 2007

    Jun 11 - Jun 14 2007
    Boca Raton, Florida, USA
    www.nimh.nih.gov/ncdeu/index.cfm
    Poster Presentation: A Survey of Investigator Beliefs About Including Adverse Events and Comorbidity Fluctuations in CNS CGI Ratings
    View PDF

    Tuesday, June 12
    12:00 – 2:00 p.m.
    Joan Busner, Ph.D.
    Clinical Manager, Clinical Operations
    Training and Education Group
    United BioSource Corporation

    Panel Session: Advances in Methodology
    Wednesday, June 13
    8:30 a.m.-12:00 p.m.
    David Daniel, MD
    Senior Vice President of United BioSource Corporation and Chief Medical Director for UBC’s Training and Education Group

  • XXVI Congress of the European Academy of Allergology and Clinical Immunology, EAACI 2007

    Jun 9 - Jun 13 2007
    Göteborg, Sweden
    www.eaaci.net/site/content.php?artid=944

    The Congestion Quantifier: A Patient-Reported Outcome Tool to Screen for and Monitor Nasal Congestion
    Stull DE¹, Canonica GW², Sandor D³, Crespi S³, Vernon MK¹; ¹United BioSource Corp.; ²Dept. of Internal Medicine, Genoa Univ.; ³ScheringPlough Corp.

  • 49th Annual Scientific Meeting of the American Headache Society

    Jun 7 - Jun 10 2007
    Chicago, IL, USA

    Poster presentations
    Cost of Migraine Stratified by Prevention Need Status in an Employer Setting
    Page MJ¹, Paramore LC², Doshi D³, Rupnow M³
    ¹HCA, United BioSource Corporation,     Bethesda, MD, USA
    ²HCA, United BioSource Corporation, Boston, MA, USA
    ³Outcomes Research, Ortho-McNeill Janssen Scientific Affairs, LLC, Titusville, NJ, USA

    Cost of Migraine Stratified by MIDAS Disability Assessment in the Workplace
    Paramore LC¹, Page MJ², Doshi D³, Rupnow M³
    ¹ HCA, United BioSource Corporation,     Boston, MA, USA
    ² HCA, United BioSource Corporation, Bethesda, MD, USA
    ³Outcomes Research, Ortho-McNeill Janssen Scientific Affairs, LLC, Titusville, NJ, USA

  • AcademyHealth 2007 Annual Research Meeting (ARM)

    Jun 3 - Jun 5 2007
    Orlando, FL, USA
    www.academyhealth.org/arm

    Methods Workshop
    Sunday, June 3, 2007, 3:00 - 4:30 PM
    Bayesian Trial Designs
    Bryan R. Luce, PhD, MBA, Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA

  • 2007 ASCO Annual Meeting

    Jun 1 - Jun 5 2007
    Chicago, IL, USA
    www.asco.org

    Abstract Presentations
    Quality of life in patients with advanced melanoma receiving vaccine therapy alone (V) or vaccine with high dose interleukin-2 (V-HIL2)
    Marden SF1, Muehlbauer P2,  Soeken K3,      Leidy NK4, Parchen D.2,  Schwartzentruber DJ5;
    1Clinical Center, National Institutes of Health, Bethesda, MD, 2Clinical Center Nursing, National Institutes of Health, Bethesda, MD, 3Consultant, Laurel, MD, 4United Biosource Inc., Bethesda, MD, 5Center for Cancer Care, Goshen Health System, Goshen, IN.

  • Magi's Clinical Trial Agreements & Budgets Conference

    May 20 - May 23 2007
    Atlantic City, NJ, USA

    Sponsor/CRO/Site Contracts: What Can We Learn from the Differences

    Morton G¹, Hochstrasser J², Prather³; ¹United BioSource Corp.; ²The Procter & Gamble Company; ³Duke Clinical Research Institute

  • ISPOR 12th Annual International Meeting

    May 19 - May 23 2007
    Arlington, VA, USA
    www.ispor.org

    Pre-Meeting Short Courses
    Saturday, May 19, 2007, 8:00 AM-5:00 PM
    Bayesian Analysis: Overview & Applications
    Faculty:  Bryan Luce PhD, MBA, Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA; Christopher S. Hollenbeak PhD, Surgery and Health Evaluation Sciences, Penn State College of Medicine, Hershey, PA, USA and Visiting Scientist, United BioSource Corporation, Center for Health Economics & Policy, Bethesda, MD, USA; David Vanness PhD, Assistant Professor of Population Health Sciences, University of Wisconsin Medical School, Madison, WI, USA

    Sunday, May 20, 2007, 8:00 AM-12:00 PM
    Bayesian Analysis: Advanced
    Faculty:  Bryan Luce PhD, MBA, Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA; Keith R. Abrams PhD, Department of Health Sciences, University of Leicester, England, U.K; Christopher S. Hollenbeak PhD, Surgery and Health Evaluation Sciences, Penn State College of Medicine, Hershey, PA, USA and Visiting Scientist, United BioSource Corporation, Center for Health Economics & Policy, Bethesda, MD, USA; David Vanness PhD, Assistant Professor of Population Health Sciences, University of Wisconsin Medical School, Madison, WI, USA

    Sunday, May 20, 2007, 8:00 AM-12:00 PM
    Real World Data Methods: Use of Real World Data in Outcomes Research
    Faculty: Diana Brixner PhD, RPh, Associate Professor and Department Chair, College of Pharmacy, University of Utah, Salt Lake City, UT;     Gregory de Lissovoy, PHD, MPH, Senior Research Scientist, United BioSource Corporation, Center for Health Economics and Policy, Bethesda, MD,USA; Daniel M. Huse, MA, Practice Leader, Information Products, Thomson Medstat Inc., Cambridge, MA, USA

    Poster Presentations
    Monday, May 21, 2007, 9:45AM-8:00PM
    Can the SF-36 Physical Function Scale Capture Functional Outcomes During Recovery from Traumatic Injury? A Review of the Literature
    Vernon MK1, Murray L1, Mannix S 1, Leidy NK1, Kelly KM2, Mody S2
    1 United BioSource Corporation, Bethesda, MD, 2Ortho–Biotech Clinical Affairs, LLC, Bridgewater, NJ

    Monday, May 21, 2007, 9:45AM-8:00PM
    Cost-Effectiveness of Achieving Additional Lipid Targets when Substituting Fenofibrate 145MG for Standard Fenofibrate Therapy
    Sorensen S1, Frick KD2, Burge R3, Simko RJ3
    1United BioSource Corporation, Bethesda, MD, USA, 2John Hopkins University, Baltimore, MD, USA, 3Abbott Laboratories, Abbott Park, IL, USA

    Monday, May 21, 2007, 9:45AM-8:00PM
    Validation of the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) in Patients with Diabetic Retinopathy
    Rousculp MD1,     Matza LS2, Malley K3, Oglesby AK1, Boye KS1
    1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Bethesda, MD, USA, 3Malley Research Programming, Inc., Rockville, MD, USA

    Tuesday, May 22, 2007, 8:00 AM-7:00 PM
    Adherence to Guidelines for Use of Erythropoiesis Stimulating Proteins in Patients with Chemotherapy-Induced Anemia: Trends from Electronic Medical Records
    Luo W1, Nordstrom B1, Ranganathan G1, Linz H1, Stokes M1, Ross SD1, Knopf K2
    1United BioSource Corporation, Medford, MA USA, 2Pacific Hematology /Oncology Associates, San Francisco, CA, USA

    Tuesday, May 22, 2007, 8:00 AM-7:00 PM
    Analyses from Routine Patient Care Settings for Clinical Research Purposes
    Ross S1, Frame D1,Winterkorn A1, Fahrbach K1 ;1 United BioSource Corporation, Boston, MA, USA 

    Tuesday, May 22, 2007, 8:00AM-7:00PM
    Can Patients with Asthma Feel Their Maintenance Inhaler Working Right Away? Reproducibility and Validity of a Weekly Diary for Assessing Perception and Satisfaction
    Leidy NK1, Patrick D2, Parasuraman B3, Petrillo J1, Mathias SD4
    1United BioSource Corporation, Bethesda, MD, USA, 2University of Washington, Seattle, WA, USA, 3AstraZeneca, Wilmington, DE, USA, 4Ovation Research Group a division of ICON Clinical Research, San Francisco, CA, USA

    Tuesday, May 22, 2007, 8:00AM-7:00PM
    Cost-Effectiveness of Linezolid in Gram-Positive Infections: Consistency of Economic Advantage from Multiple Health Care Systems 
    Duttagupta S1, Sorensen S    V2, Liu L1
    1Pfizer Inc, New York, NY, USA 2United BioSource Corporation, Bethesda, MD, USA 

    Tuesday, May 22, 2007, 8:00AM-7:00PM
    Cost-Effectiveness of New Targeted Therapy Sunitinib Malate as Second Line Treatment in Metastatic Renal Cell Carcinoma in Argentina
    Aiello EC1, Muszbek N2, Richardet E3, Lingua A3, Charbonneau C4, Remák E5
    1Pfizer Argentina, Buenos Aires, Argentina, 2United BioSource Corporation, London, UK, 3Instituto Oncológico de Córdoba, Córdoba, Argentina, 4Pfizer, New York, NY, USA, 5United BioSource Corporation, Budapest, Hungary

    Tuesday, May 22, 2007, 8:00AM-7:00PM
    Understanding Patient Perception of Therapy: Development of a Weekly Diary to Determine Whether Patients with Asthma Can Feel Their Maintenance Inhaler Working Right Away
    Mathias SD1, Parasuraman B2,     Petrillo J3, Leidy NK3
    1Ovation Research Group a division of ICON Clinical Research, San Francisco, CA, USA, 2AstraZeneca, Wilmington, DE, USA, 3United BioSource Corporation, Bethesda, MD, USA

    Workshop Sessions

    Wednesday, May 23, 2007,     8:00 AM - 9:00 AM

    WHEN STRATEGY, SCIENCE AND TECHNOLOGY CONVERGE: DEVELOPING E-DIARIES FOR PATIENT-REPORTED OUTCOMES ASSESSMENT
    DISCUSSION LEADERS:     Jennifer Petrillo, BS, Associate Project Manager, United BioSource Corporation, Bethesda, MD, USA; Laurie B. Burke, RPh, MPH, Director, FDA/CDER/OND-IO, Silver Spring, MD, USA; Pamela W. McNamara, BS, Chief Executive Officer, CRF, Inc, Waltham, MA, USA; Nancy Leidy, PhD, Senior Vice President Scientific Affairs, United BioSource Corporation, Bethesda, MD, USA

  • Digestive Disease Week

    May 19 - May 24 2007
    Washington, DC

    Presentation

    Clinical and economic impact of increased colonscopy screening in the United States: A computer simulation of a Markov process.
    Lee WC, Yeh YC, Atzinger C, Pashos CL.

  • 2007 American Thoracic Society (ATS) International Conference

    May 18 - May 23 2007
    San Francisco, CA, USA
    www.thoracic.org

    Poster Presentations
    The Impact of Practice Level Device Switching on Asthma Control
    Thomas M³, Price D³,  Williams A²,  Lloyd A¹,  Chrystyn H4
    ¹United BioSource Corporation, London, UK; ²GlaxoSmithKline, Greenford, Middlesex, UK; ³University of Aberdeen, Aberdeen, Scotland; 4University of Bradford, Bradford, West Yorkshire, UK

    What Happens to Patients Who Have Their Asthma Medication Switched without Their Consent? A Qualitative Study
    Price D³, Lloyd A¹,  Doyle S¹,  Williams A²,  Thomas M³, Chrystyn H4
    ¹United BioSource Corporation, London, UK; ²GlaxoSmithKline, Greenford, Middlesex, UK; ³University of Aberdeen, Aberdeen, Scotland; 4University of Bradford, Bradford, West Yorkshire, UK

  • ARVO Annual Meeting 2007

    May 6 - May 10 2007
    Fort Lauderdale, Florida, USA
    www.arvo.org/

    Poster Presentation
    Evaluating the Benefits of Treatments for Ophthalmic Conditions Using Cost Utility Analysis. Which Metric to Use?
    Kowalski J¹, Lloyd A², Walt J¹,     Rentz A³, Lee J¹
    ¹Allergan, Irvine, CA, USA
    ²United BioSource Corporation,     London, UK
    ³United BioSource Corporation, Bethesda, MD, USA

  • 26th Annual Scientific Meeting of the American Pain Society

    May 2 - May 5 2007
    Washington, DC, USA
    www.ampainsoc.org/meeting

    Presentations
    Development and Validation of the Modified Brief Pain Inventory Short Form (MBPI-SF) in CABG and General Surgery Patients
    Chen W1, Chan KS2, Chen C3, Lakshminarayanan M3, Revicki D1
    1United BioSource Corporation, Bethesda, MD, USA; 2Johns Hopkins School of Public Health, Baltimore, MD, USA; 3Pfizer Inc., New York, NY, USA

    Development and Validity of a Composite Clinically Meaningful Events (CMES) Score Based on the Opioid-Related Symptom Distress Scale (OR-SDS)
    Chan KS1,     Chen W2; Chen C3; Lakshminarayanan M3, Revicki D2
    1Johns Hopkins School of Public Health, Baltimore, MD, USA;  2United BioSource Corporation, Bethesda, MD, USA; 3Pfizer Inc., New York, NY, USA

  • American Geriatric Society Annual Meeting

    May 2 - May 6 2007
    Seattle, WA, USA

    Poster Presentation
    Medical Cost of Osteoporosis in the Elderly Medicare Population
    Blume S¹, Kahler KH, Paramore C, Chan W, Curtis JR, Saag K
    ¹United BioSource Corporation, Bethesda, MD, USA

  • 59th Annual Meeting of the American Academy of Neurology

    Apr 28 - May 5 2007
    Boston, MA, USA

    Poster presentations
    Screening for Migraine in an Employer Setting
    Page MJ¹, Paramore LC², Rupnow M³, Doshi D³
    ¹HCA, United BioSource Corporation,     Bethesda, MD, USA
    ²HCA, United BioSource Corporation, Boston, MA, USA
    ³Outcomes Research, Ortho-McNeill Janssen Scientific Affairs, LLC, Titusville, NJ, USA

    Burden of Migraine in the Employer Setting
    Paramore LC¹, Page MJ², Rupnow M³, Doshi D³
    ¹ HCA, United BioSource Corporation,     Boston, MA, USA
    ² HCA, United BioSource Corporation, Bethesda, MD, USA
    ³Outcomes Research, Ortho-McNeill Janssen Scientific Affairs, LLC, Titusville, NJ, USA

  • The New Evidence Landscape: The Impact of Changing Regulatory and Economic Standards on Clinical Innovation and Product Commercialization

    Apr 20 - Apr 20 2007
    New York, New York, USA

    Government and commercial payer requirements for drugs are changing. They are demanding stronger evidence of quality, safety, efficacy and value than ever before. What strategies can pharmaceutical and life sciences companies pursue to meet these requirements and get their products to market more safely and efficiently? For investors, these industry changes raise important questions that will have a direct impact on the timing of new FDA application approvals and the role of pharmaceutical outsourcing.

    Please join us on Friday, April 20, as our panel of respected industry, academic, and government thought leaders discuss these important and topical issues. Selected speakers include:

    • Dr. Mark McClellan, Former Administrator, Centers for Medicare and Medicaid Services
    • Dr. Steve Galson, Acting Director, FDA Center for Drug Evaluation and Research
    • Dr. Dan Shultz, Director, FDA Center for Devices and Radiological Health
    • Troy Brennan, MD, MPH, Chief Medical Officer, Aetna
    • Geno Germano, Executive Vice President and General Manager, Wyeth Pharmaceuticals
    • Burt Adelman, Executive Vice President, Portfolio Strategy, Biogen Idec

    Please contact conferences@unitedbiosource.com for more information.

  • National Osteoporosis Foundation 7th International Symposium on Osteoporosis

    Apr 17 - Apr 21 2007
    Washington, DC, USA

    Podium and Poster Presentation
    Medical Cost of Osteoporosis in the Elderly Medicare Population
    Blume S¹, Kahler KH, Paramore C, Chan W, Curtis JR, Saag K
    ¹United BioSource Corporation, Bethesda, MD, USA

  • Academy of Managed Care Pharmacy, 19th Annual Meeting

    Apr 11 - Apr 14 2007
    San Diego, CA

    Presentation

    Medication adherence and the health economic impact of anti-diabetic therapy conversion to an insulin analog pen device among type 2 diabetes patients.
    Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL.

  • 3rd Annual CBI Pharmaceutical Risk Management Conference

    Mar 29 - Mar 30 2007
    Philadelphia, PA, USA
    www.conf-reg.com/webreg/RegGate.wbr?HB729

    Strategies for Proposing Focused Post Marketing Studies in Your RiskMAP
    Chad Clark, SVP, Operations, United BioSource Corporation; Chairperson: Annette Stemhagen, VP, Epidemiology and Risk Management, United BioSource Corporation

  • 2007 Annual Meeting of the American Association for Geriatric Psychiatry

    Mar 1 - Mar 4 2007
    New Orleans, Louisiana, USA
    www.aagpmeeting.org

    Presentation
    Primary Care Screening for Cognitive Impairment: The PROCOG Screener (Presented at the symposium “New Developments in Dementia Screening for Older Adults”)
    Frank L1, Bowman L2, Flynn J2, Kleinman L3
    1United BioSource Corporation, Bethesda, MD, USA; 2Eli Lilly and Company, Indianapolis, IN, USA; 3United BioSource Corporation, Seattle, WA, USA

  • 2007 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

    Feb 23 - Feb 27 2007
    San Diego, CA, USA
    www.annualmeeting.aaaai.org
    Poster Presentation
    Perceived Onset of Effect of Budesonide and Formoterol Administered via One Pressurized Metered-dose Inhaler in Patients With Asthma Previously Receiving Inhaled Corticosteroids
    Leidy NK1, Patrick DL2, Boggs R3, Parasuraman B3, O'Dowd L3
    1    United BioSource Corporation, Bethesda, MD, USA; 2University of Washington, Seattle, WA, USA; 3AstraZeneca, Wilmington, DE, USA
    Assessment of the Psychometric Properties of the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) in Moderate to Severe Pediatric Asthma Patients
    Lobo FS1,     Revicki D2, Grant W3, Turk F4, Massanari M1
    1Novartis Pharmaceuticals, East Hanover, NJ, USA; 2United BioSource Corporation, Bethesda, Maryland, USA; 3James Madison University, Harrisonburg, VA, USA; 4Novartis Pharmaceuticals, Basel, Switzerland

    Prescribing of Fluticasone Propionate/Salmeterol Combinations as Initial Therapy for Patients With Asthma in a Commercially-Insured Population
    Friedman HS1,     Wilcox TK2, Reardon G3, Crespi S4, Yawn BP5
    1Analytic Solutions, LLC, New York, NY, USA; 2United Biosource Corporation, Bethesda, MD, USA; 3Informagenics, LLC, Worthington, OH, USA; 4Schering-Plough Corporation, Kenilworth, NJ, USA; 5Olmsted Medical Center, Rochester, MN, USA

  • Emerging Technologies Spine Education Summit

    Feb 7 - Feb 10 2007
    Telluride, CO, USA
    www.spinecolorado.com/conference
    Session
    The Future for Total Disk Arthroplasty: Lessons Learned from the Charite Experience.
    Isabella Sledge, MD, MPH, Medical Director, United BioSource Corporation, Boston, MA, USA